AbbVie CDR (CAD Hedged)

Federal Circuit Upholds Pfizer's Victory in Gene Therapy Patent Dispute for Hemophilia Treatment

2 days ago

• The Federal Circuit has affirmed the Patent Trial and Appeal Board's decision invalidating two patents covering experimental gene therapy for hemophilia treatment, handing Pfizer a significant legal victory. • The invalidated patents were related to novel gene therapy approaches for hemophilia, highlighting the competitive landscape in developing advanced treatments for this rare bleeding disorder. • This ruling represents an important precedent in the gene therapy intellectual property space, potentially impacting future development and commercialization of similar therapeutic approaches.

AbbVie Sues Hetero Labs Over New Orilissa Patent to Block Generic Endometriosis Drug

4 days ago

• AbbVie has filed a new patent infringement lawsuit against Hetero Labs to prevent the production of generic versions of its endometriosis drug Orilissa (elagolix sodium). • The lawsuit centers on US Patent No. 12,102,637, which was recently issued on October 1 and is licensed from Neurocrine Biosciences with protection extending for another 13 years. • This legal action represents AbbVie's expanded effort to block all potential generic competitors, with Hetero Labs being described as the "last holdout" in the company's patent protection strategy.

Pfizer Enters $6 Billion Licensing Deal with China's 3SBio for Novel Cancer Drug

5 days ago

• Pfizer has secured global rights (excluding China) to 3SBio's experimental cancer drug SSGJ-707 for $1.25 billion upfront, with potential additional payments of up to $4.8 billion based on developmental milestones. • SSGJ-707 is currently being evaluated for multiple cancer types including non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors, with Phase III trials in China planned to begin this year. • The deal includes a $100 million equity investment in 3SBio by Pfizer, with manufacturing planned at Pfizer's facilities in North Carolina and Kansas following FDA clearance of the Investigational New Drug application.

Eli Lilly Partners with Rznomics in $1.3B Deal to Develop RNA Editing Therapy for Hereditary Hearing Loss

9 days ago

• Rznomics Inc. has secured a potential $1.35 billion global license option agreement with Eli Lilly to codevelop an RNA editing-based gene therapy targeting hereditary hearing loss. • Under the partnership structure, Rznomics will lead initial R&D efforts to discover and develop the therapy, while Lilly will handle subsequent development and commercialization phases. • The deal represents a significant expansion of Lilly's gene therapy pipeline for hearing disorders, though specific details regarding up-front payments and option terms remain undisclosed.

Luveltamab Tazevibulin Shows Promising Results in Platinum-Resistant Ovarian Cancer with Low to High FRα Expression

2 months ago

• Luveltamab tazevibulin demonstrated a 32% overall response rate in platinum-resistant ovarian cancer patients with FRα expression ≥25%, showing similar efficacy in both low-medium and high expression subgroups. • The antibody-drug conjugate achieved a remarkable 96% disease control rate when administered at 5.2 mg/kg with G-CSF prophylaxis for the first two cycles, then 4.3 mg/kg in subsequent cycles. • Common side effects included arthralgia, nausea, and neutropenia, with researchers selecting the optimized dose regimen for the ongoing phase 3 portion of the REFRΑME-O1 trial.

Rheumatoid Arthritis Market Set to Reach $34.7 Billion by 2035, Driven by Novel Therapies and Rising Obesity Rates

3 months ago

• The global rheumatoid arthritis market is projected to grow from $28 billion in 2024 to $34.7 billion by 2035, with a CAGR of 1.97%, fueled by advancements in biologics and targeted therapies. • Rising obesity rates, sedentary lifestyles, and urbanization are significantly contributing to increased rheumatoid arthritis prevalence, while also reducing the efficacy of some treatments. • Novel treatment approaches including JAK inhibitors, monoclonal antibodies, and emerging therapies like R-2487 and IMVT-1402 are transforming the treatment landscape with more targeted mechanisms of action.

AbbVie's Telisotuzumab Vedotin Shows Promise in c-Met Overexpressing NSCLC

5 months ago

• AbbVie's telisotuzumab vedotin (Teliso-V) demonstrated a 35% overall response rate in patients with high c-Met expression in the LUMINOSITY trial. • The FDA granted breakthrough therapy designation to Teliso-V, highlighting its potential to significantly improve outcomes in NSCLC patients. • A phase 3 trial (TeliMET-NSCLC-01) is underway, comparing Teliso-V to docetaxel in c-Met-positive, non-squamous NSCLC patients. • Teliso-V targets c-Met, a protein involved in cancer progression and resistance to therapies like EGFR inhibitors, offering a novel approach.